Allarity Therapeutics is a biopharmaceutical company developing therapeutic candidates together with its proprietary DRP® companion diagnostics. Co.'s lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including fibroblast growth factor receptors and vascular endothelial growth factor receptor for the treatment of third line renal cell carcinoma in patients. Co.'s second therapeutic candidate is stenoparib and Co. is developing this candidate for the treatment of ovarian cancer. Co.'s third candidate is IXEMPRA® (ixabepilone), a selective microtubule inhibitor, which has been shown to interfere with cancer cell division.
|
Free ALLR Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |